A Phase 3, Randomized, Placebo-controlled, Double-blind and Open-label, Extension Study of TAS-205 in Patients With Duchenne Muscular Dystrophy
Latest Information Update: 16 Aug 2024
At a glance
- Drugs Pizuglanstat (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms REACH-DMD
- Sponsors Taiho Pharmaceutical
- 14 Aug 2024 Status changed from recruiting to active, no longer recruiting.
- 17 Aug 2023 Planned number of patients changed from 80 to 100.
- 04 Feb 2021 Status changed from not yet recruiting to recruiting.